The SARS-CoV-2 Monoclonal Antibody Combination, AZD7442, Is Protective in Non-Human Primates and Has an Extended Half-Life in Humans

The authors described AZD7442, a combination of two mAbs, AZD8895 and AZD1061, that simultaneously bound to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2.